Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: VRTX stock price vs SNA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SNA's multiple
Needs SNA P/E.
Implied fair value · at VRTX's multiple
Needs VRTX P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
17 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
VERTEX PHARMACEUTICALS INC / MA · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Snap-on Inc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
VRTX vs AMGN
Gilead Sciences, Inc.
VRTX vs GILD
BIOGEN INC.
VRTX vs BIIB
Moderna, Inc.
VRTX vs MRNA
Illumina, Inc.
VRTX vs ILMN
Trane Technologies plc
VRTX vs TT
IDEX CORP /DE/
VRTX vs IEX
SPX Technologies, Inc.
VRTX vs SPXC
Xylem Inc.
VRTX vs XYL
DOVER Corp
VRTX vs DOV
Ingersoll Rand Inc.
VRTX vs IR
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe VRTX can sustain its 31.1x earnings multiple through continued high-margin growth, then hold or add only selectively; otherwise, the data favor trimming exposure because the stock trades well above SNA-implied price of $327.64 and above the DCF range despite only moderate quality-score support.
VRTX trades at a substantial valuation premium to SNA despite only moderately better growth and materially higher profitability. The implied price of $327.64 suggests the market price of $477.10 already embeds a rich multiple that is difficult to reconcile with SNA comparison and the DCF range.
Supporting Metrics
